

Zachary J Reitman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11177136/publications.pdf>

Version: 2024-02-01

27
papers

3,843
citations

430874

18
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

7665
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 771-779.	0.8	7
2	Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients. <i>Seminars in Radiation Oncology</i> , 2022, 32, 3-14.	2.2	11
3	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604.	12.8	22
4	A Modified Nucleoside 6-Thio-2-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 6800-6814.	7.0	10
5	A Need for More Molecular Profiling in Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 785064.	2.8	1
6	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.6	18
7	Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 694-699.	2.2	18
8	New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018, 38, 050-061.	1.4	33
9	Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. <i>European Journal of Medicinal Chemistry</i> , 2016, 119, 218-230.	5.5	13
10	The genome-wide mutational landscape of pituitary adenomas. <i>Cell Research</i> , 2016, 26, 1255-1259.	12.0	137
11	Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in <i>Drosophila</i> . <i>Blood</i> , 2015, 125, 336-345.	1.4	25
12	The genetic landscape of anaplastic astrocytoma. <i>Oncotarget</i> , 2014, 5, 1452-1457.	1.8	69
13	Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma. <i>Pharmacogenomics</i> , 2014, 15, 1639-1641.	1.3	4
14	Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. <i>Journal of Biological Chemistry</i> , 2014, 289, 23318-23328.	3.4	81
15	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. <i>Nature Genetics</i> , 2014, 46, 726-730.	21.4	148
16	Mutations in <i>IDH1</i> , <i>IDH2</i> , and in the <i>TERT</i> promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014, 5, 1515-1525.	1.8	237
17	Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. <i>Acta Neuropathologica</i> , 2013, 126, 789-792.	7.7	15
18	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6021-6026.	7.1	1,202

#	ARTICLE	IF	CITATIONS
19	Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas. <i>Cancer Research</i> , 2013, 73, 496-501.	0.9	108
20	Exomic Sequencing of Four Rare Central Nervous System Tumor Types. <i>Oncotarget</i> , 2013, 4, 572-583.	1.8	69
21	Enzyme redesign guided by cancer-derived IDH1 mutations. <i>Nature Chemical Biology</i> , 2012, 8, 887-889.	8.0	22
22	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	1.8	532
23	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. <i>PLoS ONE</i> , 2011, 6, e16812.	2.5	100
24	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3270-3275.	7.1	390
25	IDH1 and IDH2: Not Your Typical Oncogenes. <i>Cancer Cell</i> , 2010, 17, 215-216.	16.8	65
26	IDH1 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 585-587.	2.1	58
27	Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. <i>Journal of the National Cancer Institute</i> , 2010, 102, 932-941.	6.3	448